Gustavo Rivero was named director of Translational Research for Hematologic Malignancies at the Tampa General Hospital Cancer Institute. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe

UCLA scientists have developed advanced miniature 3D tumor organoid models that make it possible to study glioblastoma tumors in a setting that closely mirrors the human brain, shedding light on how the aggressive cancer interacts with surrounding brain cells and the immune system to become more invasive and resistant to therapy. To access this subscriber-only […]

In the United States, 18.6 million people are living with cancer, and nearly 40% of Americans will face a cancer diagnosis in their lifetime. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled […]

Triple-negative breast cancer is one of the most aggressive and treatment-resistant cancers. It grows quickly, spreads early, and lacks hormone receptors that make it treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant. Astudy in Breast Cancer Researchpoints to a promising strategy to overcome this […]

Labcorp announced its first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide. To access this subscriber-only content please log in or subscribe.If your institution […]

The reviews of two drugs granted priority review via FDA’s new priority voucher program, Commissioner’s National Priority Voucher (CNPV) Pilot Program, have been delayed. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled […]

An argument can be made that anyone who has attempted to follow the path of spending bills on Capitol Hill over the past ten days should be evaluated for whiplash. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored […]

On Jan. 23, Shauna Erickson-Abou Zahr posted these words on her Instagram feed: “The sun dared to rise today in a sunrise he certainly would have basked in with his beautiful smile on display. At 42 years and 23 days old, the greatest human I’ve ever met took his last breath in the first minutes […]

Trodelvy (sacituzumab govitecan-hziy) was added to the NCCN Guidelines as a category 1 preferred first-line treatment option for people with metastatic triple-negative breast cancer whose disease is PD-L1 negative (CPS <10) and no germline BRCA1/2 PV. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with […]

Moderna and Merck announced median five-year follow-up data from the phase IIb KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with high-risk melanoma (stage 3/4) following complete resection. To access this subscriber-only content please log in or subscribe.If your […]

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing. To access this subscriber-only content please log in or subscribe.If your institution has a site license, […]

Dario C. Altieri, president and CEO of The Wistar Institute, director of the Ellen and Ronald Caplan Cancer Center, and Robert and Penny Fox Distinguished Professor, will step down from his leadership role, effective December 2026. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with […]

The Center for Medicare and Medicaid Services is entering negotiations with drugmakers over the price of 15 medications this year. The newly announced list includes four drugs used to treat cancer. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a […]

FDA has approved Darzalez Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility. To access this […]

Triple-negative breast cancer is one of the most aggressive and treatment-resistant cancers. It grows quickly, spreads early, and lacks hormone receptors that make it treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant. Astudy in Breast Cancer Researchpoints to a promising strategy to overcome this […]

In the United States, 18.6 million people are living with cancer, and nearly 40% of Americans will face a cancer diagnosis in their lifetime. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled […]

Anirban Maitra was named director of the Laura and Isaac Perlmutter Cancer Center. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe

NIH is suspending the addition of new human embryonic stem cell lines to the Human Embryonic Stem Cell Registry, all while looking for alternatives. The agency also issued a request for information on “emerging biotechnologies to reduce or potentially replace remaining research reliance on human embryonic stem cells.” To access this subscriber-only content please log […]

No description found

No description found

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing. To access this subscriber-only content please log in or subscribe.If your institution has a site license, […]

Of all the types of breast cancer, triple negative breast cancer is the most aggressive and lacks specific therapies. TNBC also is more likely to metastasize, or travel through the blood stream to spread to other organs, which causes most of breast cancer-related deaths each year. To access this subscriber-only content please log in or […]

A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in […]

Invalid response status code (0)